Darzalex Faspro combo benefits patients new to MM and transplant
Adding Darzalex Faspro (daratumumab and hyaluronidase) — a subcutaneous or under-the-skin formulation of Darzalex (daratumumab) — to a standard combination therapy regimen led to…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Elrexfio approved for hard-to-treat multiple myeloma patients in Europe
The European Commission has granted conditional marketing authorization to Elrexfio (elranatamab) to treat adults with multiple myeloma who received at least prior…
New cases of myeloma rose in US, mostly in young Hispanic women
A study has observed a rise in the number of new cases of myeloma in both men and women in the U.S. since the…
Blenrep works better than Darzalex as early therapy, trial data show
When added to a second-line combination therapy, Blenrep (belantamab mafodotin) — developed by GlaxoSmithKline (GSK) for relapsed or treatment-resistant …
FDA delays its decision on earlier Abecma treatment for RRMM
The U.S. Food and Drug Administration (FDA) is delaying its review of an application that seeks to allow the cell therapy Abecma (idecabtagene vicleucel) to…
1st patient dosed in Phase 1 trial of triple-target treatment ISB 2001
The first multiple myeloma patient has been dosed in a Phase 1 clinical trial evaluating the safety and efficacy of ISB 2001, Ichnos…
